Recent Updates
Recently added Catalysts

OCS-01

Phase 3

Inflammation Eye Pain | Small molecule | Ophthalmology |Oculis Holding AG|Last Updated: Jul 10, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment241
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05147233A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryPHASE3 COMPLETED 241Jun 1, 2022Jul 1, 2023Jul 10, 2025 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
OCS-01DRUGDexamethasone ophthalmic suspension, 1.5%
VehicleDRUGVehicle
Unlock Study Design Details